Epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals

Journal of Virology

Volumn 85, Issue 18, 2011, Pages 9286-9299

  Tang, Haili ^a   Robinson, James E ^b   Gnanakaran, S ^c   Li, Ming ^a   Rosenberg, Eric S ^d   Perez, Lautaro G ^a   Haynes, Barton F ^a   Liao, Hua Xin ^a   LaBranche, Celia C ^a   Korber, Bette T ^c   Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTEINE; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COCULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MOLECULAR MODEL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; VIREMIA; VIRUS NEUTRALIZATION;

AMINO ACID SUBSTITUTION; ANTIBODIES, NEUTRALIZING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; NEUTRALIZATION TESTS; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052502584     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02286-10     Document Type: Article

References (107)

1. Albert, J., et al. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112.
2. Arendrup, M., et al. 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5:303-307.
3. Arthos, J., et al. 2008. HIV-1 envelope protein binds to and signals through integrin is α4β7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9:301-309.
4. Berendsen, H. J. C., J. P. M. Postma, W. F. van Gunsteren, A. DiNola, and J. R. Haak. 1984. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81:3684-3690.
5. Binley, J. M., et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
6. Blay, W. M., et al. 2006. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J. Virol. 80:999-1014.
7. Bradney, A. P., S. Scheer, S. P. Buchbinder, and D. C. Montefiori. 1999. Neutralization-escape in human immunodeficiency virus type 1 infected long-term nonprogressors. J. Infect. Dis. 179:1264-1267.
8. Bunnik, E. M., L. Pisas, A. C. van Nuenen, and H. Schuitemaker. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
9. Bures, R., et al. 2002. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. 76:2233-2244.
10. Burton, D. R., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
11. Calarese, D. A., et al. 2003. Antibody domain exchange is an immunologic solution to carbohydrate cluster recognition. Science 300:2065-2071.
12. Case, D. A., et al. 1999. Amber 6 software. University of California, San Francisco, San Francisco, CA.
13. Center, R. J., et al. 2002. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J. Virol. 76:7863-7867.
14. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
15. Chen, B., et al. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
16. Connick, E., et al. 1996. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res. Hum. Retroviruses 12:1129-1140.
17. Cornell, W. D., et al. 1995. A second generation force-field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117:5179-5197.
18. Corti, D., et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805.
19. Darden, T., D. York, and L. Pedersen. 1993. Particle mesh Ewald: an N log (N) method for Ewald sums in large systems. J. Chem. Phys. 98:10089-10092.
20. Diskin, R., P. M. Marcovecchio, and P. J. Bjorkman. 2010. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat. Struct. Mol. Biol. 17:608-613.
21. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
22. Doria-Rose, N. A., et al. 2009. Frequency and phenotype of HIV envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83:188-199.
23. Draenert, R., et al. 2006. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J. Exp. Med. 203:529-539.
24. Faulkner, D. M., and J. Jurka. 1988. Multiple aligned sequence editor (MASE). Trends Biochem. Sci. 13:321-322.
25. Ferrantelli, F., et al. 2004. Complete protection of neonatal macaques against oral challenge with pathogenic SHIV by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189:2167-2173.
26. Frost, S. D., et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102:18514-18519.
27. Geffin, R., C. Hutto, C. Andrew, and G. B. Scott. 2003. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 310:207-215.
28. Gnanakaran, S., et al. 2007. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J. Virol. 81:4886-4891.
29. Gnanakaran, S., et al. 2010. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comp. Biol. 6:e1000955.
30. Goonetilleke, N., et al. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-1272.
31. Gray, E. S., et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81:6187-6196.
32. + T cell decline and high viral load during acute Infection. J. Virol. 85:4828-4840.
33. Hessell, A. J., et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-105.
34. Hessell, et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-955.
35. Higgins, D. G., and P. M. Sharp. 1989. Fast and sensitive multiple sequence alignments on a microcomputer. Comput. Appl. Biosci. 5:151-153.
36. Hoxie, J. A. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Immunol. 61:135-152.
37. Huang, C. C., et al. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
38. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14:33-38.
39. Kirchherr, J. L., et al. 2011. Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409:163-174.
40. Kogan, T. P., B. M. Revelle, S. Tapp, D. Scott, and P. J. Beck. 1995. A single amino acid residue can determine the ligand specificity of E-selectin. J. Biol. Chem. 270:14047-14055.
41. Kwong, P. D., et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-687.
42. Kwong, P. D., et al. 2000. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Struct. Fold Des. 8:1329-1339.
43. Kwong, P. D., et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
44. Laird, M. E., T. Igarashi, M. A. Martin, and R. C. Desrosiers. 2008. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J. Virol. 82:11054-11065.
45. Land, A., and I. Braakman. 2001. Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie 83:783-790.
46. Li, B., et al. 2006. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80:5211-5218.
47. Li, M., et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
48. Li, Y., L. Luo, N. Rasool, and C. Y. Kang. 1993. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67:584-588.
49. Li, Y., et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
50. Li, M., et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J. Virol. 80: 11776-11790.
51. Li, Y., et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059.
52. Liao, H. X., et al. 2009. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158:171-179.
53. Long, E. M., S. M. Rainwater, L. Lavreys, K. Mandaliya, and J. Overbaugh. 2002. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18:567-576.
54. Lynch, R. M., et al. 2011. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85:905-915.
55. Mascola, J. R., et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
56. Mascola, J. R., et al. 1997. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:7198-7206.
57. Mascola, J. R., and D. C. Montefiori. 2003. HIV: nature's master of disguise. Nat. Med. 9:393-394.
58. Mascola, J. R., and D. C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
59. Mascola, J. R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
60. Mikell, I., et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
61. Montefiori, D. C. 2004. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays, p. 12.11.1-12.11.15. In J. E. Coligan et al. (ed.), Current protocols in immunology. John Wiley & Sons, Hoboken, NJ.
62. Montefiori, D. C., et al. 2003. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after treatment-cessation in an HIV-1-infected individual. J. Immunol. 170:3906-3914.
63. Montefiori, D. C., T. S. Hill, H. T. T. Vo, B. D. Walker, and E. S. Rosenberg. 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75:10200-10207.
64. Moog, C., H. J. A. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
65. Moore, P. L., et al. 2008. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82:1860-1869.
66. Moore, P. L., E. S. Gray, and L. Morris. 2009. Specificity of the autologous neutralizing antibody response. Curr. Opin. HIV AIDS 4:358-363.
67. Moore, P. L., et al. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5:e1000598.
68. Muster, T., et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
69. Nandi, A., et al. 2010. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396:339-348.
70. Pancera, M., et al. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 107:1166-1171.
71. Pantophlet, R., and D. R. Burton. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
72. Parren, P. W., et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
73. Pellegrin, I., et al. 1996. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J. Acquir. Immune Defic. Syndr. 11:438-447.
74. Pilgrim, A. K., et al. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection. J. Infect. Dis. 176:924-932.
75. Posner, M. R., et al. 1991. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146:4325-4332.
76. Poss, M., and J. Overbaugh. 1999. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J. Virol. 73:5255-5264.
77. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
78. SF162P4. J. Virol. 84:3443-3453.
79. Robinson, J. E., et al. 1998. Production and characterization of rhesus monoclonal antibodies reactive with SIV gp120 from macaques immunized with an attentuated vaccine. AIDS Res. Hum. Retroviruses 14:1253-1262.
80. Rong, R., et al. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81:1350-1359.
81. Rong, R., et al. 2007. Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 81:5658-5668.
82. Rong, R., et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594.
83. Rosenberg, E. S., et al. 2000. Immune control of HIV-1 after early treatment of acute infection. Nature 407:523-526.
84. Ryckaert, J. P., G. Ciccotti, and H. C. Berendsen. 1977. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23:327-341.
85. Sagar, M., X. Wu, S. Lee, and J. Overbaugh. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598.
86. Sanders, R. W., et al. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
87. Sather, D. N., et al. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
88. Scanlan, C. N., et al. 2002. The broadly neutralizing anti-HIV-1 antibody 2G12 recognizes a cluster of 1-2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
89. Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
90. Shibata, R., et al. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-210.
91. Simek, M. D., et al. 2009. HIV-1 elite neutralizers: individuals with broad and potent neutralizing activity identified using a high throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83: 7337-7348.
92. Stamatatos, L., L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
93. Stiegler, G., et al. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17:1757-1765.
94. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
95. Tiller, T., et al. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329:112-124.
96. Trkola, A., et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
97. Volpe, J. M., L. G. Cowell, and T. B. Kepler. 2006. SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22:438-444.
98. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal new HIV-1 vaccine target. Science 326:285-289.
99. Walker, L. M., et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028.
100. Wei, X., et al. 2003. Antibody neutralization and escape. Nature 422:307-312.
101. Wyatt, R., et al. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
102. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
103. Wu, X., et al. 2010. Rational design of envelope surface identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
104. Xiang, S.-H., N. Doka, R. K. Choudhary, J. Sodroski, and J. E. Robinson. 2002. Characterization of CD4-induced epitopes on the HIV-1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18:1207-1217.
105. Zhou, T., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
106. Zhou, T., et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
107. Zwick, M. B., et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.